CellSeed Inc.
Notice Regarding Recording of Non-Operating Income/Expenses and Extraordinary Gains/Losses
During the cumulative third quarter period of the fiscal year ending December 2026, CellSeed Inc. recorded interest income and received subsidy income as non-operating income, interest expense and issuance costs related to exercise of stock acquisition rights as non-operating expenses. As extraordinary items, gain on reversion of stock acquisition rights was recorded as an extraordinary gain, and impairment loss on tangible fixed assets was recorded as an extraordinary loss. These items will be reflected in the financial summary (non-consolidated).
Key Figures
- Interest income: 4,379 thousand yen
- Subsidy income received: 2,700 thousand yen
- Interest expense: 1,245 thousand yen
- Stock issuance costs: 7,667 thousand yen
- Gain on reversion of stock acquisition rights: 2,114 thousand yen
- Impairment loss on fixed assets: 74,773 thousand yen
AI要約
Key Points of the News
In the cumulative third quarter period of the current fiscal year, non-operating income/expenses and extraordinary gains/losses were recorded. The company disclosed income such as interest and subsidies, borrowing interest and costs related to exercise of stock acquisition rights, gains from reversion of rights of retirees, and impairment losses on fixed assets. These items will be reflected in the Company’s non-consolidated financial summary for the third quarter of the fiscal year ending December 2026.
Future Impact and Notes
Since non-operating and extraordinary items can affect performance, it is necessary to pay close attention to the contents of the published financial summary. The impairment was based on a careful assessment of the recoverable amount of future cash flows and may affect future cash flow projections.
CellSeed Inc.
Company overview · Stock price · Financial data · All IR
